Menu
Search
|

Menu

Close
X

Five Prime Therapeutics Inc FPRX.OQ (NASDAQ Stock Exchange Global Select Market)

17.68 USD
-- (--)
As of 2:29 AM IST
chart
Previous Close 17.68
Open --
Volume --
3m Avg Volume 239,322
Today’s High --
Today’s Low --
52 Week High 49.21
52 Week Low 17.05
Shares Outstanding (mil) 28.90
Market Capitalization (mil) 1,122.56
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.44 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY17
18
FY16
31
FY15
380
EPS (USD)
FY17
-2.794
FY16
-2.431
FY15
7.573
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
34.12
5.77
Price to Book (MRQ)
vs sector
3.36
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-29.38
14.43
Return on Equity (TTM)
vs sector
-31.27
16.13

EXECUTIVE LEADERSHIP

Lewis Williams
Executive Chairman of the Board, Since 2018
Salary: $570,833.00
Bonus: $315,000.00
Aron Knickerbocker
President, Chief Executive Officer, Chief Operating Officer, Director, Since 2018
Salary: $418,333.00
Bonus: $155,700.00
Marc Belsky
Chief Financial Officer, Senior Vice President, Since 2013
Salary: $361,667.00
Bonus: $92,450.00
Kevin Baker
Senior Vice President, Development Sciences, Since 2016
Salary: $309,167.00
Bonus: $100,000.00
Helen Collins
Senior Vice President and Chief Medical Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

111 Oyster Point Blvd
SOUTH SAN FRANCISCO   CA   94080-1910

Phone: +1415.3655600

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.

SPONSORED STORIES